Company Reports

BridgeBio Pharma is a biotechnology company focused on bridging the gap between genetic research and unmet patient needs. Its pipeline targets Mendelian disorders, precision oncology, and gene therapy, with four programs in late-stage development.

BridgeBio reported $244 million in total revenue in the second quarter, up 120% year over year, of which Attruby contributed $222 million. BridgeBio recorded a net loss of $152 million in the second quarter. Shares were trading flat on Aug. 11.

BridgeBio reported $195 million in total first-quarter revenue. Heart drug Attruby accounted for nearly $181 million in sales, representing 24% growth from the fourth quarter and 392% year-over-year growth. Management announced a share repurchase program of up to $500 million of common stock.

BridgeBio reported fourth-quarter net revenue of $154 million, primarily driven by $146 million in Attruby sales. BridgeBio reported a net loss for 2025 of $3.78 per share. Shares traded down about 2.5% on Feb. 25.

BridgeBio reported phase 3 top-line results for infigratinib, an oral drug for achondroplasia, showing strong efficacy and safety, and posing a competitive challenge to BioMarin's approved Voxzogo. On Feb. 12, BridgeBio shares closed nearly 4% up while BioMarin shares closed flat on the news.

BridgeBio Pharma is a biotechnology company focused on bridging the gap between genetic research and unmet patient needs. Its pipeline targets Mendelian disorders, precision oncology, and gene therapy, with four programs in late-stage development.

BridgeBio reported net revenue of $120.7 million in the third quarter, driven primarily by $108 million in Attruby sales. However, the company missed FactSet EPS consensus by $0.06, and shares fell about 4% on Oct. 30.

BridgeBio Pharma is a biotechnology company focused on bridging the gap between genetic research and unmet patient needs. Its pipeline targets Mendelian disorders, precision oncology, and gene therapy, with four programs in late-stage development.

BridgeBio shares surged nearly 20% on Oct. 27 after the company announced positive phase 3 results for its small-molecule candidate BBP-418 in limb-girdle muscular dystrophy type 2I/R9, with the trial meeting all primary and secondary interim endpoints.

BridgeBio Pharma is a biotechnology company focused on bridging the gap between genetic research and unmet patient needs. Its pipeline targets Mendelian disorders, precision oncology, and gene therapy, with four programs in late-stage development.

BridgeBio Pharma reported net revenue of $110.6 million in the second quarter. Attruby sales totaled $71.5 million, with 3,751 unique prescriptions written to date. However, the company missed FactSet EPS consensus by $0.16, causing shares to tumble 10% on Aug. 6.

No-moat BridgeBio Pharma reported strong first-quarter results, driven by better-than-expected commercial success of its key asset Attruby, which generated $36.7 million in sales in the period. The results were well received by investors, with shares rising about 8% in after-hours trading. To reflect faster market penetration and a steeper near-term launch trajectory, we are increasing our fair value estimate to $41 per share from $36. At the current market price, we view the shares as fairly valued.

BridgeBio Pharma is a biotechnology company focused on bridging the gap between genetic research and unmet patient needs. Its pipeline targets Mendelian disorders, precision oncology, and gene therapy, with four programs in late-stage development.

No-moat BridgeBio reported fourth-quarter results that were largely in line with our expectations. Investors have reacted positively to BridgeBio’s recent developments and have sent the stock up 30% year to date, moving into 3-star territory close to our $36 fair value estimate. Attruby, an oral drug for ATTR-CM, is off to a strong start after it received approval in the US in November 2024. As of Feb. 17, 1,028 unique patient prescriptions for Attruby have been written by 516 distinct prescribers. It also received approval under the name Beyonttra in the EU on Feb. 10, resulting in a $75 million milestone payment from its partner Bayer and tiered royalties in the low-30s percentage range on EU sales.

BridgeBio Pharma is a biotechnology company focused on bridging the gap between genetic research and unmet patient needs. Its pipeline targets Mendelian disorders, precision oncology, and gene therapy, with four programs in late-stage development.

BridgeBio Pharma is a biotechnology company focused on bridging the gap between genetic research and unmet patient needs. Its pipeline targets Mendelian disorders, precision oncology, and gene therapy, with four programs in late-stage development.

BridgeBio's acoramidis, set to be marketed as Attruby, has secured approval from the US Food and Drug Administration for the treatment of transthyretin amyloid cardiomyopathy. We adjusted our model to account for the approval (previously a 90% probability of approval in our base case), and we have made a modest upward revision to our patient growth projections in the later years. This resulted in an increase of our fair value estimate to $36.40, up from $35.20. Investors sent shares of no-moat BridgeBio surging by 16% on this news.

No-moat BridgeBio reported soft third-quarter results that generally aligned with our expectations for an early-stage biotech firm. After reviewing our model, we are slightly decreasing our fair value estimate by 4% to $35.20 per share from $36.70 due to a slow ramp-up of sales for acoramidis in the near term. However, shares appear undervalued at the current market price.

BridgeBio Pharma is a biotechnology company focused on bridging the gap between genetic research and unmet patient needs. Its pipeline targets Mendelian disorders, precision oncology, and gene therapy, with four programs in late-stage development.

We have initiated coverage of BridgeBio Pharma, a biotechnology firm focused on discovering and delivering transformative medicine for genetic diseases. We assign the firm a no-moat rating due to the substantial risk of value destruction, as a significant portion of its valuation hinges on one pipeline candidate, acoramidis. The shares appear undervalued against our $36.70 fair value estimate.